Cancers · 2020 · 55 citations · 27 references
MedicineOncologyPathologyCancer EpidemiologyHepatologyMolecular PathologyChronic Liver DiseaseHepatic PathologyHepatobiliary PathologyHepatocellular CarcinomaLiver CancerLiver DiseaseHepatic Steatosis AssessmentLiver Cancer PrevalenceLiver Disease ComplicationsLiver Disease PrognosisLiver Disease Risk AssessmentPopulation Cancer Registries
Non-alcoholic fatty liver disease (NAFLD) and its most aggressive form, non-alcoholic steatohepatitis (NASH), are causing a rise in the prevalence of hepatocellular carcinoma. Data about NAFLD/NASH and intrahepatic cholangiocarcinoma (iCCA) are few and contradictory, coming from population registries that do not correctly distinguish between NAFLD and NASH. We evaluated the prevalence of NAFLD and NASH in peritumoral tissue of resected iCCA (n = 180) and in needle biopsies of matched liver donors. Data of iCCA patients were subsequently analysed to compare NASH-related iCCA (Group A), iCCA arisen in a healthy liver (Group B) or in patients with classical iCCA risk factors (Group C). NASH was found in 22.5% of 129 iCCA patients without known risk factors and in 6.2% of matched controls (risk ratio 3.625, 95% confidence interval 1.723–7.626, p < 0.001), while NAFLD was equally represented in both groups. The overall survival of NASH-related iCCA was inferior to that of patients with healthy liver (38.5 vs. 48.1 months, p = 0.003) and similar to that of patients with known risk factors (31.9 months, p = 0.948), regardless of liver fibrosis. The multivariable Cox regression confirmed NASH as a prognostic factor (hazard ratio 1.773, 95% confidence interval 1.156–2.718, p = 0.009). We concluded that NASH (but not NAFLD) is a risk factor for iCCA and might affect its prognosis. Dissecting NASH from NAFLD by histology is necessary to correctly assess the actual role of these conditions. Prevention protocols for NASH patients should also consider the risk for iCCA and not only HCC. Mechanistic studies aimed to find a direct pathogenic link between NASH and iCCA could add further relevant information.
27
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
David E. Kleiner, Elizabeth M. Brunt, Mark L. Van Natta et al. · Hepatology · 2005 · 10.7K citations
Mahul B. Amin, Frederick L. Greene, Stephen B. Edge et al. · CA A Cancer Journal for Clinicians · 2017 · 6.5K citations · Full text
Medicine, Cancer Biology, Oncology +17
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
John Bridgewater, Peter R. Galle, Shahid A. Khan et al. · Journal of Hepatology · 2014 · 1.5K citations
Medicine, Oncology, Pathobiology +11